ACCELERATED COMMUNICATION

Synaptic-Type $\alpha 1\beta 2\gamma 2L$ GABA_A Receptors Produce Large Persistent Currents in the Presence of Ambient GABA and Anesthetic Drugs

Ping Li and Gustav Akk

Department of Anesthesiology (P.L., G.A.) and the Taylor Family Institute for Innovative Psychiatric Research (G.A.), Washington University School of Medicine, St. Louis, Missouri

Received October 17, 2014; accepted February 9, 2015

ABSTRACT

Synaptic GABA_A receptors respond to synaptically released GABA and are considered to be unaffected by the low levels of ambient transmitter in the brain. We show that synaptic-type $\alpha 1\beta 2\gamma 2L$ GABA_A receptors expressed in HEK293 cells respond with large steady-state currents to combinations of a low concentration (0.5 μ M) of GABA and clinically used GABAergic modulators propofol, etomidate, or pentobarbital or the steroid alphaxalone. At a maximally effective concentration of modulator, the current levels at the end of 2-minute applications of drug combinations were >10%

of the peak response to saturating GABA. In the absence of modulators, 0.5 μ M GABA generated a steady-state response of 1% of the peak response to saturating GABA. The concentration-response curves for enhancement of steady-state currents by propofol, etomidate, pentobarbital, or alphaxalone were at similar or lower drug concentrations compared with concentration-response relationships for enhancement of peak responses. We propose that modulation of tonically activated synaptic-type GABA_A receptors contributes to the clinical actions of sedative drugs.

Introduction

GABA_A receptors in the brain are exposed to phasic high (near millimolar) concentrations of GABA during synaptic transmission and low ambient (<1 μ M) concentrations of GABA, which is continuously present in the cerebrospinal fluid (reviewed in Farrant and Nusser, 2005). Ambient GABA activates extrasynaptic GABA_A receptors, whose major identifying characteristics are high affinity to the transmitter and weak desensitization in the persistent presence of an agonist. The targets of phasic GABA are synaptic GABA_A receptors, which are characterized by relatively low affinity to GABA and high maximal peak open probability. The conventional view is that synaptic-type receptors are minimally affected by the presence of low ambient GABA. Indeed, the concentration of extracellular GABA (Houston et al., 2012) is several tens of folds lower than the apparent affinity to GABA of synaptic subtypes of GABA_A receptors (Li et al., 2006; Picton and Fisher, 2007).

Under physiologic conditions, GABA_A receptors, including synaptic receptors, are exposed to endogenous modulators such as neuroactive steroids (Carver and Reddy, 2013). Under clinical conditions, GABA_A receptors can be exposed to GABAergic sedative drugs such as propofol, etomidate, or barbiturates. Although these drugs are ineffective at modulating peak

responses of synaptic events due to saturation of GABA binding and a high maximal open probability of GABA-activated receptors, there remains a possibility that GABAergic modulators potentiate the low-level activity from synaptic-type receptors exposed to ambient GABA.

To test this hypothesis, we exposed heterologously expressed rat $\alpha 1\beta 2\gamma 2L$ receptors to a low concentration (0.5 μ M) of GABA, intended to mimic steady-state GABA, in the absence and presence of several common modulators of the GABA_A receptor. The data show that a combination of a low concentration of GABA with clinical concentrations of propofol, etomidate, pentobarbital, or the steroid alphaxalone enhances the level of quasi-steady-state current by ~10-fold. Concentration-response measurements indicate that the EC₅₀s for potentiation of steady-state currents are at similar or lower concentrations than those measured for potentiation of peak responses. Our data raise the possibility of a role for tonically activated synaptic-type GABA_A receptors in the clinical actions of some anesthetic drugs.

Materials and Methods

Experiments were carried out on rat wild-type $\alpha 1\beta 2\gamma 2L$ GABA_A receptors. Receptors were transiently expressed in HEK293 cells, using a modified calcium phosphate precipitation-based transient transfection technique (Akk, 2002). The amino terminus of the $\alpha 1$ subunit was tagged with the FLAG epitope (Ueno et al., 1996), and bead-binding with immunobeads against the FLAG epitope was used to identify cells expressing high levels of GABA_A receptors.

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grants P01-GM047969 and R01-GM108580].

dx.doi.org/10.1124/mol.114.096453.

Electrophysiological recordings were done on lifted cells using the standard whole-cell voltage-clamp approach. Cells were clamped at -60 mV. Recordings were conducted at room temperature. The bath solution contained the following (in mM): NaCl, 140; KCl, 5; MgCl₂, 1; CaCl₂, 2; D-glucose, 10; and HEPES, 10 (pH 7.4). The pipette solution contained the following (in mM): CsCl, 140; NaCl, 4; MgCl₂, 4; CaCl₂, 0.5; EGTA, 5; and HEPES, 10 (pH 7.4). Agonist (GABA) and modulators (propofol, etomidate, pentobarbital, or alphaxalone) were applied onto cells through bath using an SF-77B fast perfusion stepper system (Warner Instruments, Hamden, CT). We have previously found that the solution exchange time with this system is 10–20 milliseconds with a typical-size HEK cell (Li and Akk, 2008). Durations of drug applications were 2 minutes in most recordings. Consecutive drug applications were separated by 2- to 4-minute washouts in bath solution. The currents were recorded using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA), low-pass filtered at 2 kHz and digitized with a Digidata 1320 series interface (Molecular Devices) at 10 kHz. The analysis of current traces was conducted using pClamp 9.0 software (Molecular Devices). Current traces were analyzed with respect to the amplitudes of peak and residual currents at the end of a 2-minute drug application. No visually noticeable current decay was observed at the end of 2-minute applications when 0.5 μ M GABA was coapplied with modulators. Each cell was also exposed to 50 μ M GABA to obtain a reference point for maximal peak response. This concentration, at ~ 5 times the macroscopic EC₅₀ value (Li et al., 2006), produces a near-maximal response. Amplitudes of responses to low GABA and combinations of low GABA and modulators are expressed as percentage of the peak response to 50 μ M GABA from the same cell. The data are reported as mean $\pm$ S.E.M.

Concentration-response curves were fitted, individually for each cell, with the following equation:

$$Y = Y_{\min} + (Y_{\max} - Y_{\min}) \times \left(\frac{[\text{drug}]}{[\text{drug}] + \text{EC}_{50}} \right)^n$$

where EC₅₀ is the concentration of drug producing a half-maximal effect, n describes the slope of relationship, and $Y_{\min}$ and $Y_{\max}$ are the low- and high-concentration asymptotes, respectively. Fitting was conducted using the NFIT software (University of Texas Medical Branch at Galveston, Galveston, TX). Parameters of the fit are reported as mean $\pm$ S.E.M.

The potentiating effect of alphaxalone on steady-state current elicited by GABA is given as response ratio, calculated as response in the presence of steroid divided by response in the absence of steroid. Statistical analysis was performed using Excel (Microsoft, Redmond, WA). Statistical significance was determined by comparing the response ratio to 1, i.e., no effect, using a two-tailed paired t test. This test is equivalent to a one-sample t test with a hypothetical value of 1, and is designed to verify whether the effect of the drug is statistically significant.

GABA, inorganic salts used in buffers, pentobarbital, and alphaxalone were bought from Sigma-Aldrich (St. Louis, MO). Propofol was

from MP Biomedicals (Solon, OH). Etomidate was purchased from R&D Systems (Minneapolis, MN).

Results

Rat $\alpha 1\beta 2\gamma 2\text{L}$ GABA_A receptors expressed in HEK293 cells have a whole-cell GABA EC₅₀ of ~ 10 μ M (Li et al., 2006). Activation of $\alpha 1\beta 2\gamma 2\text{L}$ receptors by 50 μ M GABA resulted in fast-rising large inward currents that desensitized to $14 \pm 1\%$ (mean $\pm$ S.E.M.; 14 cells) of the peak response by the end of a 2-minute drug application. Exposure of same set of cells to 0.5 μ M GABA elicited a peak response that was $3 \pm 1\%$ and a steady-state current that was $1 \pm 1\%$ of the peak response to 50 μ M GABA. Sample currents are shown in Fig. 1, A and B.

The anesthetic compound propofol potentiates currents from $\alpha 1\beta 2\gamma 2\text{L}$ receptors activated by submaximal concentrations of GABA (Ruesch et al., 2012). We found that coapplication of 1 μ M propofol with 0.5 μ M GABA potentiated the peak response by 7 ± 2 -fold (14 cells). Propofol alone at this concentration elicited a negligible response ($0.3 \pm 0.1\%$ of the peak response to 50 μ M GABA). The current at the end of a 2-minute drug application was enhanced by 14 ± 5 -fold when 1 μ M propofol was coapplied with 0.5 μ M GABA. Relative to the peak response to 50 μ M GABA, the steady-state current at the end of a 2-minute application of 0.5 μ M GABA + 1 μ M propofol was $9 \pm 2\%$ (14 cells).

To investigate the concentration-response relationship of propofol-elicited enhancement of steady-state currents, we tested, in a separate set of five cells, the effect of 0.1 – 3 μ M propofol on steady-state currents elicited by low GABA. Compared with the peak response to 50 μ M GABA in the same cell, the mean current level at the end of a 2-minute drug application was $2 \pm 1\%$, $5 \pm 1\%$, $8 \pm 2\%$, or $8 \pm 1\%$ in the presence of 0.5 μ M GABA and 0.1 , 0.3 , 1 , and 3 μ M propofol, respectively. Curve-fitting the data from each cell individually yielded an EC₅₀ of 0.44 ± 0.06 μ M and a Hill coefficient of 2.4 ± 0.6 (mean $\pm$ S.E.M.; Fig. 2B). The fit maximum was $9 \pm 1\%$ (five cells).

To determine whether other common GABA_A receptor potentiators modulate steady-state currents from $\alpha 1\beta 2\gamma 2\text{L}$ receptors, we examined the effects of etomidate and pentobarbital on currents elicited by 0.5 μ M GABA. Coapplication of 0.1 – 10 μ M etomidate with 0.5 μ M GABA enhanced steady-state current. The relative (compared with peak in the presence of 50 μ M GABA) steady-state current levels were $1.3 \pm 0.4\%$, $3 \pm 1\%$, $6 \pm 1\%$, $11 \pm 1\%$, or $11 \pm 1\%$ when receptors were activated by 0.5 μ M GABA in the presence of

Fig. 1. Activation of rat $\alpha 1\beta 2\gamma 2\text{L}$ GABA_A receptors by GABA. Currents were elicited by 2-minute applications of 50 μ M GABA (A) or 0.5 μ M GABA (B). In (B), the framed inset shows the same current trace at a higher current resolution. Traces in (A) and (B) are from the same cell.

Fig. 2. Exposure to propofol (PRO) enhances steady-state currents from $\alpha 1\beta 2\gamma 2\text{L}$ GABA_A receptors. (A) Sample current responses from receptors activated by 50 μM GABA (red line), 0.5 μM GABA (blue line), or 0.5 μM GABA + 0.1, 0.3, 1, or 3 μM propofol (black lines). For clarity, only the first 10 seconds of the 50 μM GABA trace are shown. The inset shows the final 30 seconds of the traces. All traces are from the same cell. (B) A concentration-response relationship for propofol-induced enhancement of steady-state currents. The steady-state currents were normalized to the peak response to 50 μM GABA from the same cells. Data show mean $\pm$ S.E.M. from a set of five cells. The curve shows the prediction of the equation $Y = Y_{\min} + (Y_{\max} - Y_{\min}) \times ([\text{propofol}] / ([\text{propofol}] + \text{EC}_{50}))^n$, where EC_{50} is the concentration of propofol producing a half-maximal effect, n is the slope of the curve, and $Y_{\min}$ and $Y_{\max}$ are the low- and high-concentration asymptotes, respectively. The curve was generated with the overall mean parameters from the five cells. The EC_{50} was $0.44 \pm 0.06 \mu\text{M}$ (mean $\pm$ S.E.M.), n was 2.4 ± 0.6 , and $Y_{\max}$ was $9 \pm 1\%$. The value for $Y_{\min}$ was held at the value obtained from the relative steady-state current from the same five cells in the presence of 0.5 μM GABA alone ($1 \pm 0.3\%$).

0.1, 0.3, 1, 3, or 10 μM etomidate, respectively (a set of seven cells). Curve-fitting yielded an EC_{50} of $0.9 \pm 0.4 \mu\text{M}$, a Hill coefficient of 2.2 ± 0.4 , and a fitted maximal response of $11 \pm 1\%$. Sample traces and the concentration-response plot are shown in Fig. 3A.

Steady-state currents elicited by 0.5 μM GABA were also enhanced in the presence of pentobarbital. Coapplication of 3, 10, 30, or 100 μM pentobarbital with GABA resulted in relative current levels of $2 \pm 1\%$, $6 \pm 1\%$, $13 \pm 1\%$, or $12 \pm 2\%$ (five cells at each condition), respectively. Curve-fitting yielded an EC_{50} of $12 \pm 2 \mu\text{M}$, a Hill coefficient of 2.6 ± 0.4 , and a maximal current level of $13 \pm 2\%$ (Fig. 3B).

We previously showed that the application of a neuroactive steroid enhances peak responses from $\alpha 1\beta 2\gamma 2\text{L}$ GABA_A receptors activated by allosteric activators or combinations of low GABA and an allosteric activator (Li et al., 2014). To test whether a steroid can enhance steady-state currents from receptors activated by GABA and an allosteric drug, we coapplied 10–1000 nM alphaxalone with 0.5 μM GABA + 1 μM propofol. Due to numerous controls and comparisons in this experimental protocol, the effects of increasing concentrations of steroid were tested on separate cells. The steady-state current level at the end of a 2-minute application was $8 \pm 1\%$ (10 nM alphaxalone; three cells), $15 \pm 2\%$ (30 nM; three cells), $11 \pm 2\%$ (100 nM; three cells), $10 \pm 2\%$ (300 nM; four cells), and $16 \pm 6\%$ (1000 nM; three cells) of the peak response to 50 μM GABA. These values were not significantly different (two-sample t test; Excel) from the mean steady-state response observed for 0.5 μM GABA + 1 μM propofol in the absence of alphaxalone ($9 \pm 2\%$ of the peak response to 50 μM GABA; see above). Sample traces are shown in Fig. 3C.

To verify that alphaxalone is capable of potentiating steady-state responses to GABA alone, we evaluated data obtained as part of the experimental protocol in the preceding experiment where each cell had additionally been challenged with 0.5 μM GABA + alphaxalone. In six cells exposed to 0.5 μM GABA + 1000 nM alphaxalone, the steady-state response at the end of

a 2-minute drug application was $9 \pm 2\%$ of the peak response to 50 μM GABA. This represented an 11 ± 2 -fold increase in the current level compared with steady-state response to 0.5 μM GABA alone in the same set of cells. Note that the number of cells here is greater than in the preceding experiment because not all cells yielded data for all drug conditions. Analogous data evaluation for other steroid concentrations showed that steady-state currents from receptors activated by 0.5 μM GABA were potentiated by 2.4 ± 0.3 -fold (11 cells) and 4.1 ± 0.4 -fold (4 cells) in the presence of 100 and 300 nM alphaxalone, respectively. Coapplication of 10 or 30 nM alphaxalone with 0.5 μM GABA had a statistically insignificant effect on steady-state response. We infer that alphaxalone concentration-dependently enhances steady-state response to low GABA. Sample current traces and the concentration-response relationship are given in Fig. 3C.

Discussion

The potentiating effects of GABA_A receptor modulators are typically studied with regard to effect on the peak response. Here, we demonstrate that some common, clinically used GABA_A receptor potentiators (propofol, etomidate, pentobarbital, and the steroid alphaxalone) potentiate quasi-steady-state currents from $\alpha 1\beta 2\gamma 2\text{L}$ receptors activated by 0.5 μM GABA. The steady-state response under control conditions was 1% of the peak response to saturating GABA. At a maximally effective concentration of modulator, the amplitude of steady-state current was potentiated by ~ 10 -fold.

GABA_A receptors containing $\alpha 1\beta 2\gamma 2\text{L}$ receptors have a high (>0.8) maximal open probability in the presence of GABA (Steinbach and Akk, 2001). This predicts that the steady-state open probability of $\alpha 1\beta 2\gamma 2\text{L}$ receptors in the presence of 0.5 μM GABA and propofol, etomidate, pentobarbital, or alphaxalone reaches ~ 0.1 . Although the latter value may be overestimated if rapid desensitization reduces the maximal peak estimate, we believe that the error is insignificant, for

Fig. 3. Exposure to etomidate, pentobarbital, or alphaxalone enhances steady-state currents from $\alpha 1\beta 2\gamma 2\text{L}$ GABA_A receptors. (A) Sample current responses from receptors activated by 50 μM GABA (red line), 0.5 μM GABA (blue line), or 0.5 μM GABA + 10 μM etomidate (ETO; black line). For clarity, only the first 10 seconds of the 50 μM GABA trace are shown. All traces are from the same cell. The lower portion of (A) shows the concentration-response relationship for etomidate-induced enhancement of steady-state current levels. The steady-state currents were normalized to the peak response to 50 μM GABA from the same cells. Data show mean $\pm$ S.E.M. from seven cells exposed to 0.5 μM GABA and 0.1–10 μM etomidate. The curve was generated as in Fig. 2 with the following overall parameters: $\text{EC}_{50} = 0.9 \pm 0.4 \mu\text{M}$, $n = 2.2 \pm 0.4$, $Y_{\min} = 0.6 \pm 0.2\%$, $Y_{\max} = 11 \pm 1\%$. (B) Sample current traces from receptors activated by 50 μM GABA (red line), 0.5 μM GABA (blue line), or 0.5 μM GABA + 100 μM pentobarbital (PEB; black line). The lower portion of (B) shows the concentration-response relationship for pentobarbital-induced enhancement of steady-state current levels. Data show mean $\pm$ S.E.M. from five cells exposed to 0.5 μM GABA and 3–100 μM pentobarbital. The curve was generated as in Fig. 2 with the following overall parameters: $\text{EC}_{50} = 12 \pm 2 \mu\text{M}$, $n = 2.6 \pm 0.4$, $Y_{\min} = 0.7 \pm 0.1\%$, $Y_{\max} = 13 \pm 2\%$. (C) Sample current traces from receptors activated by 50 μM GABA (red line), 0.5 μM GABA (blue line), 0.5 μM GABA + 1 μM alphaxalone (ALF; black line), or 0.5 μM GABA + 1 μM alphaxalone + 1 μM propofol (PRO; gray line). The lower portion of (C) shows the effect of 10, 30, 100, 300, or 1000 nM alphaxalone on steady-state responses to 0.5 μM GABA. The data give mean $\pm$ S.E.M. for the response ratio (1 = no effect) from 4–11 cells at each steroid concentration. All data points were obtained from individual cells. Statistical analysis was conducted by comparing the response ratio to 1 using two-tailed paired t test (Excel). * $P < 0.05$; ** $P < 0.01$; † $P > 0.05$.

the following reasons. First, a more rapid solution exchange when 1 mM, instead of 50 μM , GABA is used to activate receptors has only minor effect on the peak response. Second, the peak response to saturating GABA is minimally affected by potentiators, indicative of high open probability during peak current. Finally, our relative steady-state responses to saturating GABA are generally similar to those obtained from rapid drug applications to excised patches (e.g., Haas and Macdonald, 1999).

The EC_{50} s for potentiation of steady-state currents from $\alpha 1\beta 2\gamma 2\text{L}$ were similar or lower than the EC_{50} s from available data for potentiation of peak responses. For example, we estimate that the half-maximal concentration of etomidate producing an increase of steady-state currents is 0.9 μM (Fig. 3A), whereas our recent study on the effect of etomidate on peak currents from $\alpha 1\beta 2\gamma 2\text{L}$ receptors revealed an EC_{50} of

2 μM (Li et al., 2014). Similarly, while the EC_{50} for potentiation of steady-state currents by propofol was 0.4 μM (Fig. 2B), estimates for EC_{50} for potentiation of peak currents from $\alpha 1\beta 2\gamma 2$ receptors range from 2 (Krasowski et al., 2001) to 25 μM (Lam and Reynolds, 1998). The differences in EC_{50} estimates may be due to state dependence of potentiation or simply reflect greater occupancy of the transmitter site in steady-state recordings.

The concentration of free propofol in plasma of surgical patients is $\sim 1.3 \mu\text{M}$ (Rehberg and Duch, 1999). Thus, potentiation of steady-state currents from $\alpha 1\beta 2\gamma 2\text{L}$ receptors may contribute to the sedative effect of propofol. The concentration of steady-state GABA to which the receptors are exposed under physiologic conditions is estimated at or below 0.5 μM (multiple references in Houston et al., 2012). Although exposure of $\alpha 1\beta 2\gamma 2\text{L}$ to 0.5 μM GABA elicited an

almost negligible response (1% of the response to saturating GABA), the combination of 0.5 μ M GABA and 1 μ M propofol is expected to generate a steady level of ~10% of maximal activity from these receptors.

Maximal steady-state current levels were similar for other potentiators. Coapplication of 100 μ M pentobarbital with 0.5 μ M GABA produced steady-state activity that was 12% of the peak response to 50 μ M GABA. The mean steady-state current was 11% of the maximal peak response in the presence of 0.5 μ M GABA and 10 μ M etomidate, and 9% in the presence of 0.5 μ M GABA and 1000 nM alphaxalone. Interestingly, the addition of 10–1000 nM alphaxalone to the combination of 0.5 μ M GABA + 1 μ M propofol did not lead to further enhancement of steady-state current. This is in contrast to our recent finding that neuroactive steroids can potentiate peak currents elicited by a combination of GABA and an allosteric activator (Li et al., 2014).

The ambient GABA concentration is likely dynamic, showing greater fluctuations at or near the synapse where the high-millimolar concentration of GABA during a synaptic event rapidly drops due to uptake and diffusion. A recent study found that the ability of GABA_A receptor potentiators to enhance tonic currents depends on ambient GABA concentration (Houston et al., 2012). This introduces yet another variable capable of affecting the final level of tonic inhibition in the presence of sedative drugs.

Two major questions are raised by these observations. The first is the mechanism by which the steady-state response is enhanced. One possibility is that desensitization is reduced. This notion is supported by prior work that showed slower desensitization or potentiation of steady-state currents elicited by saturating GABA in the presence of some anesthetic drugs (Feng and Macdonald, 2004; Feng et al., 2004; Hall et al., 2004). Potentiation of steady-state currents from receptors activated by low concentrations of GABA additionally includes an effect on channel gating. Our data obtained with 0.5 μ M GABA demonstrate a major contribution from gating given that the peak response, for which desensitization-based effect is minimal, was enhanced by 7-fold, whereas the steady-state response, sensitive to changes in both desensitization and gating, was enhanced by 14-fold during coapplication with 1 μ M propofol. In future single-channel work, it will be interesting to determine the precise kinetic makeup of potentiation of currents elicited by ambient GABA.

The second question relates to the physiologic consequences of the additional, tonic current. Receptors containing the $\alpha 1$ and $\gamma 2$ subunits constitute the majority of GABA_A receptors in the brain (Whiting et al., 1999). If it is assumed that these receptors are present at about 10-fold-higher numbers than the classic tonic receptors (largely $\alpha 4/\delta$ or $\alpha 5/\gamma 2$ subtypes), then the steady-state contribution we have demonstrated would be a considerable additional tonic inhibitory influence on the cells. This rough calculation will require much more refinement as information on the relative numbers of different receptor types is gathered, as well as further studies on the abilities of these modulators to enhance responses to endogenous levels of GABA. There is evidence that $\alpha 1/\gamma 2$ receptors can be located outside the immediate postsynaptic membrane (Thomas et al., 2005; Mortensen and Smart, 2006; Kasugai et al., 2010). This pool of extrasynaptically located $\alpha 1/\gamma 2$ GABA_A receptors is expected to be minimally active in

the presence of steady-state GABA but respond with an ~10-fold increase in current amplitude during exposure to anesthetics. Unlike synaptic $\alpha 1/\gamma 2$ receptors that undergo periodic activation and desensitization by high-millimolar concentrations of GABA, extrasynaptic $\alpha 1/\gamma 2$ receptors would be ideally suited to provide steady inhibitory current until exposure to the anesthetic is terminated.

To recapitulate, the data show that synaptic-type $\alpha 1\beta 2\gamma 2$ GABA_A receptors exposed to a low, steady-state concentration of GABA and clinical concentrations of several anesthetic drugs produce persistent currents that have an amplitude of ~10% of the maximal peak response. This type of potentiation of inhibitory tone is distinct from the anesthetic-mediated prolongation of synaptic currents or enhancement of tonic inhibition mediated by classic $\alpha 4/6$ - or $\alpha 5$ -containing extrasynaptic receptors. We propose that these persistent, non-desensitizing currents from $\alpha 1\beta 2\gamma 2$ GABA_A receptors, in addition to previously identified anesthetic targets or modes of potentiation, contribute to the clinical effects of anesthetic drugs.

Acknowledgments

The authors thank Dr. J. H. Steinbach for many fruitful discussions during the course of the study.

Authorship Contributions

Participated in research design: Akk.

Conducted experiments: Li.

Performed data analysis: Li, Akk.

Wrote or contributed to the writing of the manuscript: Li, Akk.

References

- Akk G (2002) Contributions of the non-alpha subunit residues (loop D) to agonist binding and channel gating in the muscle nicotinic acetylcholine receptor. *J Physiol* 544:695–705.
- Carver CM and Reddy DS (2013) Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. *Psychopharmacology (Berl)* 230: 151–188.
- Farrant M and Nusser Z (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *Nat Rev Neurosci* 6:215–229.
- Feng HJ, Bianchi MT, and Macdonald RL (2004) Pentobarbital differentially modulates $\alpha 1\beta 2\gamma 2$ and $\alpha 1\beta 3\gamma 2$ GABA_A receptor currents. *Mol Pharmacol* 66:988–1003.
- Feng HJ and Macdonald RL (2004) Multiple actions of propofol on $\alpha 1\beta 2\gamma 2$ and $\alpha 1\beta 3\gamma 2$ GABA_A receptors. *Mol Pharmacol* 66:1517–1524.
- Haas KF and Macdonald RL (1999) GABA_A receptor subunit $\gamma 2$ and δ subtypes confer unique kinetic properties on recombinant GABA_A receptor currents in mouse fibroblasts. *J Physiol* 514:27–45.
- Hall AC, Rowan KC, Stevens RJN, Kelley JC, and Harrison NL (2004) The effects of isoflurane on desensitized wild-type and $\alpha 1(S270H)$ γ -aminobutyric acid type A receptors. *Anesth Analg* 98:1297–1304.
- Houston CM, McGee TP, Mackenzie G, Troyano-Cuturi K, Rodriguez PM, Kutsarova E, Diamanti E, Hosie AM, Franks NP, and Brickley SG (2012) Are extrasynaptic GABA_A receptors important targets for sedative/hypnotic drugs? *J Neurosci* 32: 3887–3897.
- Kasugai Y, Swinny JD, Roberts JDB, Dalezios Y, Fukazawa Y, Sieghart W, Shigemoto R, and Somogyi P (2010) Quantitative localisation of synaptic and extrasynaptic GABA_A receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immunolabelling. *Eur J Neurosci* 32:1868–1888.
- Krasowski MD, Jenkins A, Flood P, Kung AY, Hopfinger AJ, and Harrison NL (2001) General anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of γ -aminobutyric acid (GABA) current at the GABA(A) receptor but not with lipid solubility. *J Pharmacol Exp Ther* 297:338–351.
- Lam DW and Reynolds JN (1998) Modulatory and direct effects of propofol on recombinant GABA_A receptors expressed in xenopus oocytes: influence of α - and γ -subunits. *Brain Res* 784:179–187.
- Li P and Akk G (2008) The insecticide fipronil and its metabolite fipronil sulphone inhibit the rat $\alpha 1\beta 2\gamma 2$ GABA(A) receptor. *Br J Pharmacol* 155: 783–794.
- Li P, Bracamontes JR, Manion BD, Mennerick S, Steinbach JH, Evers AS, and Akk G (2014) The neurosteroid 5β -pregnan-3 α -ol-20-one enhances actions of etomidate as a positive allosteric modulator of $\alpha 1\beta 2\gamma 2$ GABA_A receptors. *Br J Pharmacol* 171: 5446–5457.
- Li P, Covey DF, Steinbach JH, and Akk G (2006) Dual potentiating and inhibitory actions of a benz[e]indene neurosteroid analog on recombinant $\alpha 1\beta 2\gamma 2$ GABA_A receptors. *Mol Pharmacol* 69:2015–2026.

- Mortensen M and Smart TG (2006) Extrasynaptic alphabeta subunit GABAA receptors on rat hippocampal pyramidal neurons. *J Physiol* **577**:841–856.
- Picton AJ and Fisher JL (2007) Effect of the alpha subunit subtype on the macroscopic kinetic properties of recombinant GABA(A) receptors. *Brain Res* **1165**:40–49.
- Rehberg B and Duch DS (1999) Suppression of central nervous system sodium channels by propofol. *Anesthesiology* **91**:512–520.
- Ruesch D, Neumann E, Wulf H, and Forman SA (2012) An allosteric coagonist model for propofol effects on $\alpha 1\beta 2\gamma 2\text{L}$ γ -aminobutyric acid type A receptors. *Anesthesiology* **116**:47–55.
- Steinbach JH and Akk G (2001) Modulation of GABA(A) receptor channel gating by pentobarbital. *J Physiol* **537**:715–733.
- Thomas P, Mortensen M, Hosie AM, and Smart TG (2005) Dynamic mobility of functional GABAA receptors at inhibitory synapses. *Nat Neurosci* **8**:889–897.
- Ueno S, Zorumski C, Bracamontes J, and Steinbach JH (1996) Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells. *Mol Pharmacol* **50**:931–938.
- Whiting PJ, Bonnert TP, McKernan RM, Farrar S, Le Bourdellès B, Heavens RP, Smith DW, Hewson L, Rigby MR, and Sirinathsinghji DJ et al. (1999) Molecular and functional diversity of the expanding GABA-A receptor gene family. *Ann N Y Acad Sci* **868**:645–653.

Address correspondence to: Gustav Akk, Department of Anesthesiology, Washington University, Campus Box 8054, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail: akk@morpheus.wustl.edu